ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Joseph Abi Jaoude
Matched on ORCID iD 0000-0002-2283-4765; OpenAlex author ID A5042435815. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper
Papers 8
- Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
- Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. First author DOI 10.1186/s12885-022-09255-3↗
- Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. First author DOI 10.1016/j.adro.2020.11.006↗
- Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Co-author DOI 10.1016/j.adro.2021.100763↗
- ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-21-0519↗
- Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer. Co-author DOI 10.3390/metabo11090627↗
- Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. Co-author DOI 10.1016/j.currproblcancer.2020.100607↗
- Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. First author DOI 10.3390/cancers12092487↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Cullen M. Taniguchi · 8 shared papers, 2020–2023 · strength 1.08
- Paper ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer. DOI 10.1158/0008-5472.can-21-0519↗
- Paper Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. DOI 10.1186/s12885-022-09255-3↗
- Paper Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer. DOI 10.3390/metabo11090627↗
- Nicholas D. Nguyen · 5 shared papers, 2020–2021 · strength 0.59
- Paper Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer. DOI 10.3390/metabo11090627↗
- Paper Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. DOI 10.1016/j.currproblcancer.2020.100607↗
- Paper Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. DOI 10.3390/cancers12092487↗
- Ethan Bernard Ludmir · 4 shared papers, 2020–2023 · strength 0.48
- Paper Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. DOI 10.1016/j.currproblcancer.2020.100607↗
- Paper Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. DOI 10.3390/cancers12092487↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Carolina J. García García · 3 shared papers, 2021–2022 · strength 0.47
- Paper ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer. DOI 10.1158/0008-5472.can-21-0519↗
- Paper Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. DOI 10.1186/s12885-022-09255-3↗
- Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
- Ramez Kouzy · 4 shared papers, 2020–2021 · strength 0.46
- Paper Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. DOI 10.1016/j.currproblcancer.2020.100607↗
- Paper Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. DOI 10.3390/cancers12092487↗
- Paper Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. DOI 10.1016/j.adro.2021.100763↗
- Daniel Lin · 4 shared papers, 2020–2021 · strength 0.46
- Paper Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. DOI 10.1016/j.currproblcancer.2020.100607↗
- Paper Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. DOI 10.3390/cancers12092487↗
- Paper Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. DOI 10.1016/j.adro.2021.100763↗
- Joseph M. Herman · 3 shared papers, 2021–2023 · strength 0.33
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. DOI 10.1016/j.adro.2021.100763↗
- Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
- Eugene Jon Koay · 3 shared papers, 2021–2023 · strength 0.33
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. DOI 10.1016/j.adro.2021.100763↗
- Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
- Matthew H. G. Katz · 2 shared papers, 2021–2023 · strength 0.23
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. DOI 10.1016/j.adro.2021.100763↗
- Shalini Moningi · 2 shared papers, 2021–2023 · strength 0.22
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
- Manoop S. Bhutani · 2 shared papers, 2021–2023 · strength 0.22
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
- Albert C. Koong · 2 shared papers, 2021 · strength 0.20
- Paper Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. DOI 10.1016/j.adro.2021.100763↗
- Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
- Abagail M. Delahoussaye · 1 shared paper, 2022 · strength 0.15
- Tara N. Fujimoto · 1 shared paper, 2022 · strength 0.15
- Meifang Yu · 1 shared paper, 2021 · strength 0.13
- Brian G. Czito · 1 shared paper, 2023 · strength 0.12
- Gabriel Oliveira Sawakuchi · 1 shared paper, 2023 · strength 0.12
- Lauren Elizabeth Colbert · 1 shared paper, 2023 · strength 0.12
- Dae Won Kim · 1 shared paper, 2023 · strength 0.12
- Jessica M. Frakes · 1 shared paper, 2023 · strength 0.12
- Todd Anthony Aguilera · 1 shared paper, 2023 · strength 0.12
- Robert A. Wolff · 1 shared paper, 2023 · strength 0.12
- Manisha Palta · 1 shared paper, 2023 · strength 0.12
- Vincent Bernard · 1 shared paper, 2023 · strength 0.12
- Rebecca S. Slack Tidwell · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.